Evidence map›Paper›PMID 41284133›Full record

Trial reportUnited European gastroenterology journal2026

Remimazolam Enables Faster Sedation Induction and Recovery Compared With Midazolam in Diagnostic Upper Gastrointestinal Endoscopy: A Multicenter Randomized Controlled Trial.

Yehyun Park, Jun Kyu Lee, Kwang Hyuck Lee, Taejun Kim, Sun Hyung Kang, Dong-Won Ahn, Sung Bum Kim, Seong-Jung Kim

Registry-linked trialAbstract readClinical Trial, Phase IIIEquivalence TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in United European gastroenterology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05836545 (A Randomized, Single-Blind, Investigator Initiative Trial Study of Remimazolam Versus Midazolam for Sedation in Diagnostic Upper Gastrointestinal Endoscopy), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05836545 phase3completednot on this map

A Randomized, Single-Blind, Investigator Initiative Trial Study of Remimazolam Versus Midazolam for Sedation in Diagnostic Upper Gastrointestinal Endoscopy

TypeinterventionalSponsorSamsung Medical CenterRan2023 to 2024Enrolled132ConditionsHealthyArmsRemimazolam, Midazolam
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yehyun ParkDepartment of Internal Medicine, Ewha Womans University Seoul Hospital, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0001-8811-0631
Jun Kyu LeeDepartment of Internal Medicine, Dongguk University College of Medicine, Dongguk University Ilsan Hospital, Goyang, Republic of Korea.ORCID https://orcid.org/0000-0002-2694-3598
Kwang Hyuck LeeDivision of Gastroenterology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0002-2898-6233
Taejun KimDivision of Gastroenterology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0001-8101-9034
Sun Hyung KangDepartment of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Republic of Korea.ORCID https://orcid.org/0000-0002-1913-4346
Dong-Won AhnDepartment of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0002-6641-2177
Sung Bum KimDepartment of Internal Medicine, Yeungnam University College of Medicine, Daegu, Republic of Korea.ORCID https://orcid.org/0000-0001-8447-2176
Seong-Jung KimDepartment of Internal Medicine, College of Medicine, Chosun University, Gwangju, Republic of Korea.ORCID https://orcid.org/0000-0003-1456-941X

Funding

HANA PHARM, CO., LTD
6 · The paper itself

Abstract

BACKGROUND AND

aimsRemimazolam, a new ultra-short-acting benzodiazepine, is a safe and effective option for procedural sedation. Nevertheless, to date, no study has directly compared remimazolam and midazolam in diagnostic upper gastrointestinal endoscopy. This study aimed to evaluate the efficacy and safety of remimazolam compared with those of midazolam in this setting.

methodsThis multicenter, single-blind, randomized, positive-control, superiority, investigator-initiated phase III trial enrolled patients who were scheduled to undergo diagnostic upper gastrointestinal endoscopy at seven academic teaching hospitals from April 2023 to January 2024. Participants were randomly assigned to receive remimazolam or midazolam (1:1 ratio). The primary endpoint was total procedure time, defined as the duration from the first sedative administration to discharge.

resultsOf 133 randomized patients, 132 (remimazolam group, n = 66; midazolam group, n = 66) underwent upper endoscopy with sedation. The total procedure time was significantly shorter in the remimazolam group (30.3 vs. 48.5 min, p < 0.001). Sedation-related times (i.e., induction, sedation, recovery, and discharge times) were also significantly shorter in the remimazolam group (all p < 0.001). The incidence of adverse events did not significantly differ between the groups; however, the incidence rates of hypotension, bradycardia, and paradoxical reactions were lower in the remimazolam group. When compared to previous sedation experiences, patient satisfaction was higher in the remimazolam group (p < 0.001).

conclusionsCompared with midazolam, the use of remimazolam in diagnostic upper gastrointestinal endoscopy allows for faster sedation induction and recovery, more rapid discharge, and higher patient satisfaction compared with previous sedation experiences, while maintaining a safety profile similar to that of midazolam.

trial registrationClinicalTrials.gov (NCT05836545).

Indexed as

BenzodiazepinesEndoscopy, GastrointestinalHypnotics and SedativesMidazolamProcedural SedationAdultAgedAnesthesia Recovery PeriodFemaleHumansMaleMiddle AgedSingle-Blind MethodTime FactorsBenzodiazepinesHypnotics and SedativesMidazolamremimazolambenzodiazepineendoscopymidazolamremimazolamsedation

Identifiers

PMID41284133
PMCPMC12811999

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.